农村卫生系统应优先选择哪种 psychedelic 治疗：裸盖菇素还是伊博因？

Rural health systems encounter disproportionate behavioral health burdens, including higher suicide rates, overdose mortality, poverty, and reduced access to specialty mental health and addiction care. As psychedelic-assisted therapies move toward possible clinical implementation, rural leaders may need to decide which therapies merit investment planning. This point–counterpoint compares psilocybin and ibogaine from a rural health system perspective rather than as a conventional pharmacologic review. Psilocybin currently has a more developed clinical evidence base, service delivery model, and